Ali Noursina

Dr. Ali Noursina

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MSMaryam Soheilipour
Maryam Soheilipour
ANAli Noursina
Ali Noursina
MNMohadese Nekookhoo
Mohadese Nekookhoo
EMElena Malekpour
Elena Malekpour
SMSeyed Arsham Mirzaei
Seyed Arsham Mirzaei
FSFarzad Safari
Farzad Safari
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide. Emerging evidence highlights the gut microbiota, particularly Akkermansia muciniphila, as a key modulator in CRC pathogenesis. While often regarded as a beneficial commensal, its role in CRC appears complex and potentially dualistic. This systematic review aims to comprehensively analyze the context-dependent role of A. muciniphila in CRC, evaluating its potential as a pathobiont. We systematically reviewed human, animal, in vitro, and ex vivo studies on associations between A. muciniphila and CRC risk or outcomes. Database searches identified 34 eligible studies. Study quality was assessed using the GRADE criteria. From 244 initial records, 34 studies met the inclusion criteria. Findings reveal a stark dichotomy: non-viable forms of A. muciniphila—including pasteurized bacteria, outer membrane vesicles (OMVs), and purified proteins (e.g., Amuc_1100, Amuc_2172, Amuc_1434*)—consistently demonstrate anti-tumorigenic effects. These components enhance anti-tumor immunity by activating CD8 + T cells, promoting M1-like macrophage polarization via TLR2/NLRP3 signaling, and sensitizing tumors to chemotherapy and anti-PD-1 immunotherapy. Conversely, administration of live A. muciniphila can exert pro-tumorigenic effects, particularly in inflammatory contexts (e.g., colitis-associated CRC) or post-antibiotic settings, likely due to excessive mucin degradation and gut barrier disruption. Host factors such as obesity, sex, genetics, and microbial interactions further modulate its impact. A. muciniphila functions as a pathobiont in CRC, with its role critically dependent on its biological state and host context. Therapeutic strategies should shift from live probiotics to targeted postbiotic applications of its beneficial components to maximize efficacy and safety.

24 April 2023 in Burns
Verified
Journal Article
Closed access
MSMansour Siavash
Mansour Siavash
ANAli Noursina
Ali Noursina

4 April 2024 in Journal of Preventive Epidemiology
Verified
Journal Article
Open access
FSFarzad Safari
Farzad Safari
ANAli Noursina
Ali Noursina
YVYasaman Vahdani
Yasaman Vahdani
RVRohollah Valizadeh
Rohollah Valizadeh
Hamid NasriHamid Nasri
Hamid Nasri
Lorundrostat is an aldosterone synthase inhibitor that can be used in patients with uncontrolled hypertension. It effectively lowers blood pressure, but there are concerns about the limited renal safety data available for lorundrostat. In order to address this issue, it is recommended that future research should incorporate more detailed kidney assessments, which would include monitoring for conditions such as proteinuria and acute kidney injury (AKI). This paper discusses the effects of lorundrostat on the estimated glomerular filtration rate (eGFR) and highlights the significant variability in these effects among individuals. The research shows that lorundrostat may cause a decline in eGFR exceeding one standard deviation above the mean change in approximately 16% of patients. In severe cases, 0.2% of patients may experience eGFR declines of ≥42 mL/min/1.73 m². These declines in eGFR could increase chronic kidney disease (CKD) stages, even in those with baseline eGFR >60 or 90 mL/min/1.73 m². In conclusion, while most lorundrostat patients do not experience severe eGFR declines, there is still a risk of clinically meaningful declines and CKD progression, particularly among susceptible individuals. Further research is needed to confirm these findings and identify renal risk factors in uncontrolled hypertension patients who receive aldosterone synthase inhibition.

27 December 2025 in Probiotics and Antimicrobial Proteins
Verified
Journal Article
Closed access
PDF file
FSFarzad Safari
Farzad Safari
FGFaraz Golafshan
Faraz Golafshan
EMElena Malekpour
Elena Malekpour
SMSeyed Arsham Mirzaei
Seyed Arsham Mirzaei
HRHanieh Rouzbahani
Hanieh Rouzbahani
ANAli Noursina
Ali Noursina

15 October 2026 in Advances in Redox Research
Verified
Journal Article
Open access
FAFatemeh Abbasi
Fatemeh Abbasi
MCMohammad Reza Chitsazi
Mohammad Reza Chitsazi
MSMohammad Hossein Shafieyoun
Mohammad Hossein Shafieyoun
SMSeyed Arash Mirzaei
Seyed Arash Mirzaei
HRHanieh Rouzbahani
Hanieh Rouzbahani
FSFarzad Safari
Farzad Safari

1 January 2026 in Journal of Research in Medical Sciences
Verified
Journal Article
Open access
MCMohammad Reza Chitsazi
Mohammad Reza Chitsazi
FSFarzad Safari
Farzad Safari
EMElena Malekpour
Elena Malekpour
SMSeyed Arsham Mirzaei
Seyed Arsham Mirzaei
MSMohammad Hossein Shafieyoun
Mohammad Hossein Shafieyoun
MSMansour Siavash
Mansour Siavash
Diabetic kidney disease (DKD) affects 30%–40% of patients with diabetes mellitus (DM). Dyslipidemia is a key modifiable risk factor for the development and progression of DKD. Statins remain the mainstay of lipid management in DM, but concerns exist about their renal effects and limited impact on high-density lipoprotein (HDL) and triglycerides. Fibrates, which primarily target HDL elevation and triglyceride reduction, have shown promise in addressing the lipid profile most relevant to DKD; however, they initially raise serum creatinine levels. This review aims to compare the effects of statins and fibrates on the development and progression of DKD, examining their mechanisms of action, clinical evidence, and limitations of current research. A comprehensive search of PubMed, Scopus, and Web of Science identified clinical studies published from 2000 onward, evaluating the renal effects of statins and/or fibrates in patients with DM, focusing on kidney function, damage markers, and disease progression. According to our findings, statins offer modest, short-term kidney protection; however, their long-term renal effects, and their limited impact on the specific dyslipidemia pattern associated with DKD, are a concern. Fibrates, which more effectively target triglycerides and HDL, show promise in preserving kidney function, though their use may be limited in advanced kidney disease. While some evidence suggests fibrates may be superior, especially in patients with low HDL and high triglycerides, more long-term studies are needed to confirm their definitive advantage over statins. Future research should focus on long-term studies with comprehensive assessments of kidney function.